Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $7.00M |
| Net Income (Most Recent Fiscal Year) | $-83.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -61.15% |
| Return on Assets (Trailing 12 Months) | -50.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.31M |
| Free Float | 6.55M |
| Market Capitalization | $30.47M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 67.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |